Pfizer Settles Lipitor Battles With Ranbaxy

Law360, New York (June 18, 2008, 12:00 AM EDT) -- Pfizer Inc. has reached an agreement with generics maker Ranbaxy Laboratories Ltd. to settle most of the worldwide patent litigation between the two companies over the blockbuster cholesterol-reducing treatment Lipitor.

Under the settlement, Ranbaxy will be able to sell generic versions of Lipitor and Caduet starting Nov. 20, 2011. Caduet is a combination of Lipitor and a high blood pressure medication called Norvasc, another Pfizer product.

Lipitor is the world's most prescribed drug, with worldwide sales in 2007 of $12.7 billion. The largest market for Lipitor...
To view the full article, register now.